NRG 200 Pharmacology for Human Caring Nursing Midterm
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions
NRG 200 Pharmacology for Human Caring Nursing Midterm Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation document for NRG 200 Pharmacology for Human
Caring Nursing contains 200 verified questions with correct answers, designed to align with the
2026/2027 academic year curriculum. It covers essential pharmacological principles, drug
classifications, nursing implications, and patient education, ensuring a thorough review for nursing
students. Each question is accompanied by a rationale to reinforce understanding and application. This
resource is ideal for self-assessment and mastery of pharmacology concepts.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Nursing process and medication administration
Patient education and safety
Legal and ethical considerations
Case-based clinical scenarios
Updates for 2026:
- Updated to reflect 2026/2027 NCLEX-RN test plan
- Incorporated latest FDA drug approvals and safety alerts
- Enhanced rationales for evidence-based practice
- Added new questions on emerging therapies and precision medicine
- Revised to align with current nursing pharmacology guidelines
Abstract:
This exam preparation document for NRG 200 Pharmacology for Human Caring Nursing is meticulously crafted to
facilitate mastery of pharmacological principles essential for safe and effective nursing practice. The 200 questions
are strategically distributed across core content areas, including pharmacokinetics, pharmacodynamics, drug
classifications, and nursing implications. Each question is designed to test critical thinking and clinical
application, with detailed rationales that explain the correct answer and common misconceptions. The document
integrates current evidence-based practices and aligns with the 2026/2027 academic standards, ensuring
relevance and accuracy. It serves as an indispensable tool for students aiming to excel in their midterm
examination and build a solid foundation for advanced nursing roles. The inclusion of case-based scenarios and
patient education topics enhances the practical utility of this resource, bridging theoretical knowledge with
real-world clinical situations.
Keywords:
NRG 200, Pharmacology, Nursing, Midterm Exam, Verified Questions, 2026/2027, Drug Classifications, Nursing
Implications
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining why it is correct and why the other options are incorrect.
Rationales include relevant nursing considerations, drug interactions, and patient teaching points to enhance
learning.
Page 1
,Compliance Checklist:
Aligned with 2026/2027 NRG 200 course objectives
Updated to reflect current NCLEX-RN test plan
Includes evidence-based rationales for each answer
Covers all major pharmacological content areas
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 31-60 Cholinergics, Anticholinergics, Adrenergics, 15%
Drugs Adrenergic Blockers
Cardiovascular and Renal Drugs 61-90 Antihypertensives, Diuretics, Cardiac 15%
Glycosides, Antiarrhythmics
Central Nervous System Drugs 91-120 Analgesics, Anxiolytics, Antidepressants, 15%
Anticonvulsants
Endocrine and Metabolic Drugs 121-150 Insulin, Oral Hypoglycemics, Thyroid 15%
Hormones, Corticosteroids
Antimicrobial and 151-180 Antibiotics, Antivirals, NSAIDs, 15%
Anti-inflammatory Drugs Immunosuppressants
Nursing Process and Patient 181-200 Medication Administration, Adverse Effects, 10%
Education Drug Interactions, Patient Teaching
Page 2
,Q1. A patient with chronic heart failure stabilized on digoxin is initiated on
amiodarone for atrial fibrillation. Which pharmacokinetic interaction is most likely
to necessitate a digoxin dose reduction?
A. Amiodarone inhibits P-glycoprotein, reducing renal tubular secretion of digoxin
B. Amiodarone induces CYP3A4, increasing digoxin metabolism
C. Amiodarone displaces digoxin from plasma protein binding sites, increasing free
drug concentration
D. Amiodarone decreases gastric motility, enhancing digoxin absorption
Correct Answer: A. Amiodarone inhibits P-glycoprotein, reducing renal tubular
secretion of digoxin
Rationale: Amiodarone is a potent inhibitor of P-glycoprotein, which is responsible for the
renal tubular secretion of digoxin. This inhibition reduces digoxin clearance, raising
serum digoxin levels and increasing the risk of toxicity. The other options describe
mechanisms not primarily involved in this interaction.
Why Wrong:
B - Amiodarone is a CYP3A4 inhibitor, not an inducer, and digoxin is not
significantly metabolized by CYP3A4.
C - Digoxin is not highly protein-bound, so displacement is not a significant
interaction mechanism.
D - Amiodarone does not significantly alter gastric motility; the primary interaction is
at the renal transporter level.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 22, 24
Q2. Which pharmacodynamic principle best explains why a patient with opioid
tolerance requires a higher dose of morphine to achieve the same analgesic effect?
A. Increased metabolism of morphine due to enzyme induction
B. Downregulation of mu-opioid receptors in the central nervous system
C. Decreased blood-brain barrier permeability to morphine
D. Enhanced renal clearance of morphine and its active metabolites
Correct Answer: B. Downregulation of mu-opioid receptors in the central nervous
system
Rationale: Chronic opioid exposure leads to receptor desensitization and downregulation,
reducing the number of functional mu-opioid receptors. This pharmacodynamic tolerance
necessitates higher doses to achieve the same effect. Pharmacokinetic changes
(metabolism, clearance) are less significant in opioid tolerance.
Why Wrong:
A - Enzyme induction can occur but is not the primary mechanism for opioid
tolerance; pharmacodynamic changes predominate.
C - Blood-brain barrier permeability is generally unchanged; tolerance is
Page 3
, receptor-mediated.
D - Renal clearance changes do not explain the need for higher doses; tolerance is a
pharmacodynamic phenomenon.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15, 31
Q3. A patient with type 2 diabetes is started on metformin. Which statement
accurately reflects the drug's mechanism and a key nursing consideration?
A. Metformin increases insulin secretion from pancreatic beta cells; monitor for
hypoglycemia
B. Metformin reduces hepatic glucose production and improves insulin sensitivity;
monitor renal function
C. Metformin delays carbohydrate absorption in the gut; monitor for weight gain
D. Metformin enhances glucose uptake in skeletal muscle; monitor for lactic acidosis in
patients with normal renal function
Correct Answer: B. Metformin reduces hepatic glucose production and improves
insulin sensitivity; monitor renal function
Rationale: Metformin primarily decreases hepatic gluconeogenesis and increases
peripheral insulin sensitivity, without increasing insulin secretion. It is contraindicated in
renal impairment due to the risk of lactic acidosis; monitoring renal function is essential.
Hypoglycemia is uncommon with metformin monotherapy.
Why Wrong:
A - Metformin does not stimulate insulin secretion; that is the action of sulfonylureas.
C - Metformin does not delay carbohydrate absorption; that is acarbose. It is not
associated with weight gain; it may cause weight loss.
D - Metformin does enhance peripheral glucose uptake, but lactic acidosis risk is
highest with renal impairment, not normal renal function.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 41
Q4. A patient on warfarin therapy is prescribed a course of
trimethoprim-sulfamethoxazole (TMP-SMX) for a urinary tract infection. What is
the most significant drug interaction and its mechanism?
A. TMP-SMX inhibits CYP2C9, increasing warfarin levels and INR
B. TMP-SMX displaces warfarin from albumin, increasing free warfarin concentration
C. TMP-SMX reduces vitamin K absorption, potentiating warfarin effect
D. TMP-SMX induces CYP1A2, decreasing warfarin levels and INR
Correct Answer: A. TMP-SMX inhibits CYP2C9, increasing warfarin levels and INR
Rationale: Sulfamethoxazole inhibits CYP2C9, the enzyme responsible for metabolizing
the S-enantiomer of warfarin, leading to increased warfarin levels and INR. This can
cause bleeding. The other mechanisms are not the primary interaction.
Page 4
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions
NRG 200 Pharmacology for Human Caring Nursing Midterm Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation document for NRG 200 Pharmacology for Human
Caring Nursing contains 200 verified questions with correct answers, designed to align with the
2026/2027 academic year curriculum. It covers essential pharmacological principles, drug
classifications, nursing implications, and patient education, ensuring a thorough review for nursing
students. Each question is accompanied by a rationale to reinforce understanding and application. This
resource is ideal for self-assessment and mastery of pharmacology concepts.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Nursing process and medication administration
Patient education and safety
Legal and ethical considerations
Case-based clinical scenarios
Updates for 2026:
- Updated to reflect 2026/2027 NCLEX-RN test plan
- Incorporated latest FDA drug approvals and safety alerts
- Enhanced rationales for evidence-based practice
- Added new questions on emerging therapies and precision medicine
- Revised to align with current nursing pharmacology guidelines
Abstract:
This exam preparation document for NRG 200 Pharmacology for Human Caring Nursing is meticulously crafted to
facilitate mastery of pharmacological principles essential for safe and effective nursing practice. The 200 questions
are strategically distributed across core content areas, including pharmacokinetics, pharmacodynamics, drug
classifications, and nursing implications. Each question is designed to test critical thinking and clinical
application, with detailed rationales that explain the correct answer and common misconceptions. The document
integrates current evidence-based practices and aligns with the 2026/2027 academic standards, ensuring
relevance and accuracy. It serves as an indispensable tool for students aiming to excel in their midterm
examination and build a solid foundation for advanced nursing roles. The inclusion of case-based scenarios and
patient education topics enhances the practical utility of this resource, bridging theoretical knowledge with
real-world clinical situations.
Keywords:
NRG 200, Pharmacology, Nursing, Midterm Exam, Verified Questions, 2026/2027, Drug Classifications, Nursing
Implications
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining why it is correct and why the other options are incorrect.
Rationales include relevant nursing considerations, drug interactions, and patient teaching points to enhance
learning.
Page 1
,Compliance Checklist:
Aligned with 2026/2027 NRG 200 course objectives
Updated to reflect current NCLEX-RN test plan
Includes evidence-based rationales for each answer
Covers all major pharmacological content areas
Verified for accuracy by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 31-60 Cholinergics, Anticholinergics, Adrenergics, 15%
Drugs Adrenergic Blockers
Cardiovascular and Renal Drugs 61-90 Antihypertensives, Diuretics, Cardiac 15%
Glycosides, Antiarrhythmics
Central Nervous System Drugs 91-120 Analgesics, Anxiolytics, Antidepressants, 15%
Anticonvulsants
Endocrine and Metabolic Drugs 121-150 Insulin, Oral Hypoglycemics, Thyroid 15%
Hormones, Corticosteroids
Antimicrobial and 151-180 Antibiotics, Antivirals, NSAIDs, 15%
Anti-inflammatory Drugs Immunosuppressants
Nursing Process and Patient 181-200 Medication Administration, Adverse Effects, 10%
Education Drug Interactions, Patient Teaching
Page 2
,Q1. A patient with chronic heart failure stabilized on digoxin is initiated on
amiodarone for atrial fibrillation. Which pharmacokinetic interaction is most likely
to necessitate a digoxin dose reduction?
A. Amiodarone inhibits P-glycoprotein, reducing renal tubular secretion of digoxin
B. Amiodarone induces CYP3A4, increasing digoxin metabolism
C. Amiodarone displaces digoxin from plasma protein binding sites, increasing free
drug concentration
D. Amiodarone decreases gastric motility, enhancing digoxin absorption
Correct Answer: A. Amiodarone inhibits P-glycoprotein, reducing renal tubular
secretion of digoxin
Rationale: Amiodarone is a potent inhibitor of P-glycoprotein, which is responsible for the
renal tubular secretion of digoxin. This inhibition reduces digoxin clearance, raising
serum digoxin levels and increasing the risk of toxicity. The other options describe
mechanisms not primarily involved in this interaction.
Why Wrong:
B - Amiodarone is a CYP3A4 inhibitor, not an inducer, and digoxin is not
significantly metabolized by CYP3A4.
C - Digoxin is not highly protein-bound, so displacement is not a significant
interaction mechanism.
D - Amiodarone does not significantly alter gastric motility; the primary interaction is
at the renal transporter level.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 22, 24
Q2. Which pharmacodynamic principle best explains why a patient with opioid
tolerance requires a higher dose of morphine to achieve the same analgesic effect?
A. Increased metabolism of morphine due to enzyme induction
B. Downregulation of mu-opioid receptors in the central nervous system
C. Decreased blood-brain barrier permeability to morphine
D. Enhanced renal clearance of morphine and its active metabolites
Correct Answer: B. Downregulation of mu-opioid receptors in the central nervous
system
Rationale: Chronic opioid exposure leads to receptor desensitization and downregulation,
reducing the number of functional mu-opioid receptors. This pharmacodynamic tolerance
necessitates higher doses to achieve the same effect. Pharmacokinetic changes
(metabolism, clearance) are less significant in opioid tolerance.
Why Wrong:
A - Enzyme induction can occur but is not the primary mechanism for opioid
tolerance; pharmacodynamic changes predominate.
C - Blood-brain barrier permeability is generally unchanged; tolerance is
Page 3
, receptor-mediated.
D - Renal clearance changes do not explain the need for higher doses; tolerance is a
pharmacodynamic phenomenon.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15, 31
Q3. A patient with type 2 diabetes is started on metformin. Which statement
accurately reflects the drug's mechanism and a key nursing consideration?
A. Metformin increases insulin secretion from pancreatic beta cells; monitor for
hypoglycemia
B. Metformin reduces hepatic glucose production and improves insulin sensitivity;
monitor renal function
C. Metformin delays carbohydrate absorption in the gut; monitor for weight gain
D. Metformin enhances glucose uptake in skeletal muscle; monitor for lactic acidosis in
patients with normal renal function
Correct Answer: B. Metformin reduces hepatic glucose production and improves
insulin sensitivity; monitor renal function
Rationale: Metformin primarily decreases hepatic gluconeogenesis and increases
peripheral insulin sensitivity, without increasing insulin secretion. It is contraindicated in
renal impairment due to the risk of lactic acidosis; monitoring renal function is essential.
Hypoglycemia is uncommon with metformin monotherapy.
Why Wrong:
A - Metformin does not stimulate insulin secretion; that is the action of sulfonylureas.
C - Metformin does not delay carbohydrate absorption; that is acarbose. It is not
associated with weight gain; it may cause weight loss.
D - Metformin does enhance peripheral glucose uptake, but lactic acidosis risk is
highest with renal impairment, not normal renal function.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 41
Q4. A patient on warfarin therapy is prescribed a course of
trimethoprim-sulfamethoxazole (TMP-SMX) for a urinary tract infection. What is
the most significant drug interaction and its mechanism?
A. TMP-SMX inhibits CYP2C9, increasing warfarin levels and INR
B. TMP-SMX displaces warfarin from albumin, increasing free warfarin concentration
C. TMP-SMX reduces vitamin K absorption, potentiating warfarin effect
D. TMP-SMX induces CYP1A2, decreasing warfarin levels and INR
Correct Answer: A. TMP-SMX inhibits CYP2C9, increasing warfarin levels and INR
Rationale: Sulfamethoxazole inhibits CYP2C9, the enzyme responsible for metabolizing
the S-enantiomer of warfarin, leading to increased warfarin levels and INR. This can
cause bleeding. The other mechanisms are not the primary interaction.
Page 4
